Literature DB >> 187335

Composition, associated tissue methyltransferase activity, and catabolic end products of transfer RNA from carcinogen-induced hepatoma and normal monkey livers.

D B Lakings, T P Waalkes, E Borek, C W Gehrke, J E Mrochek, J Longmore, R H Adamson.   

Abstract

This investigation was designed to explore transfer RNA (TRNA) methyltransferase activity, urinary excretion levels of tRNA degradation products, and tRNA base composition in normal monkeys and in those with hepatocellular carcinomas induced by N-nitrosodiethylamine. After the development of the tumor, 24-hr urine specimens were collected, the monkeys were sacrificed, and the livers were removed for tRNA isolation and methyltransferase activity studies. The tRNA methyltransferase activity and capacity and the urinary excretion levels for selected tRNA degradation products (pseudouridine, N2,N2-dimethylguanosine, 1-methylinosine, 7-methylguanine, and beta-aminoisobutyric acid) were elevated for the hepatoma-bearing monkeys when compared to those with normal liver. The isolated tRNA pools were analyzed by high-resolution liquid chromatography, and similar base compositions were found for the hepatoma-bearing and normal monkeys. With the use of methyl-deficient Escherichia coli tRNA as the methyl receptor and the analytical procedure for tRNA anlysis, the methylating ability of the tRNA methyltransferases in hepatoma and normal liver extracts was determined. The hepatoma methyltransferase homogenates were found to produce increased levels of 7-methylguanine, N2,N2-dimethylguanine, and thymine, while the normal liver extracts gave higher levels of N2-methylguanine. These differences were not apparent in the base composition of the tRNA pools. The increased urinary excretion and higher methyltransferase activity of the hepatoma-bearing monkeys without an apparent increase in the methylated base content of their tRNA suggest increased tRNA tf individual isoaccepting tRNA's would be missed by analyzing the tRNA pools. The variations in the individual tRNA methyltransferase activities of the hepatoma and normal liver homogenates indicate a difference in the methlation of their tRNA's.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 187335

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

Review 1.  The Many Virtues of tRNA-derived Stress-induced RNAs (tiRNAs): Discovering Novel Mechanisms of Stress Response and Effect on Human Health.

Authors:  Mridusmita Saikia; Maria Hatzoglou
Journal:  J Biol Chem       Date:  2015-10-13       Impact factor: 5.157

Review 2.  Extracellular tRNAs and tRNA-derived fragments.

Authors:  Juan Pablo Tosar; Alfonso Cayota
Journal:  RNA Biol       Date:  2020-02-19       Impact factor: 4.652

Review 3.  Non-coding RNAs as liquid biopsy biomarkers in cancer.

Authors:  Shusuke Toden; Ajay Goel
Journal:  Br J Cancer       Date:  2022-01-10       Impact factor: 7.640

4.  Pseudouridine and uridine in normal kidney and kidney cancer tissues.

Authors:  K Koshida; J Harmenberg; E Borgström; B Wahren; L Andersson
Journal:  Urol Res       Date:  1985

Review 5.  tRNA fragments in human health and disease.

Authors:  Paul Anderson; Pavel Ivanov
Journal:  FEBS Lett       Date:  2014-09-16       Impact factor: 4.124

Review 6.  Non-coding RNAs and potential therapeutic targeting in cancer.

Authors:  Shusuke Toden; Timothy J Zumwalt; Ajay Goel
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-12-13       Impact factor: 10.680

7.  Modified nucleosides: an accurate tumour marker for clinical diagnosis of cancer, early detection and therapy control.

Authors:  A Seidel; S Brunner; P Seidel; G I Fritz; O Herbarth
Journal:  Br J Cancer       Date:  2006-06-05       Impact factor: 7.640

8.  Non‑invasive prostate cancer detection by measuring miRNA variants (isomiRs) in urine extracellular vesicles.

Authors:  Danijela Koppers-Lalic; Michael Hackenberg; Renee de Menezes; Branislav Misovic; Magda Wachalska; Albert Geldof; Nicoletta Zini; Theo de Reijke; Thomas Wurdinger; Andre Vis; Jeroen van Moorselaar; Michiel Pegtel; Irene Bijnsdorp
Journal:  Oncotarget       Date:  2016-04-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.